Back to Search
Start Over
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
- Source :
-
Biomolecules [Biomolecules] 2023 Sep 02; Vol. 13 (9). Date of Electronic Publication: 2023 Sep 02. - Publication Year :
- 2023
-
Abstract
- The main protease (M <superscript>pro</superscript> ) plays a pivotal role in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target. Disruption of the catalytic activity of M <superscript>pro</superscript> produces a detrimental effect on the course of the infection, making this target one of the most attractive for the treatment of COVID-19. The current success of the SARS-CoV-2 M <superscript>pro</superscript> inhibitor Nirmatrelvir, the first oral drug for the treatment of severe forms of COVID-19, has further focused the attention of researchers on this important viral target, making the search for new M <superscript>pro</superscript> inhibitors a thriving and exciting field for the development of antiviral drugs active against SARS-CoV-2 and related coronaviruses.
- Subjects :
- Humans
Leucine analogs & derivatives
Leucine pharmacology
Proline analogs & derivatives
Proline pharmacology
Lactams
Nitriles
SARS-CoV-2 drug effects
SARS-CoV-2 enzymology
COVID-19 Drug Treatment
Coronavirus 3C Proteases antagonists & inhibitors
Coronavirus 3C Proteases metabolism
Coronavirus 3C Proteases chemistry
Antiviral Agents pharmacology
Antiviral Agents therapeutic use
Antiviral Agents chemistry
Protease Inhibitors pharmacology
Protease Inhibitors chemistry
Protease Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2218-273X
- Volume :
- 13
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Biomolecules
- Publication Type :
- Academic Journal
- Accession number :
- 37759739
- Full Text :
- https://doi.org/10.3390/biom13091339